Yes, Depo-Provera (depot medroxyprogesterone acetate, or DMPA) is linked to bone mineral density (BMD) loss. The shot lowers estrogen, and bone responds. Most of the loss happens in the first two years, and in adults much of it appears to recover after you stop. Teens and young adults, who are still building bone, are the group researchers worry about most. This guide covers the numbers, the recovery timeline, who has more to think about, and when a DEXA scan can give you a measured answer instead of a guess.
TL;DR
- The 2024 FDA label reports mean hip and spine BMD decreases of 5–6% after up to 5 years of use in adults.
- Most loss comes early: a 2006 study found about 75% of hip loss and 90% of spine loss occurred in the first 24 months.
- Adults usually recover partially or fully after stopping. Adolescents treated for more than two years did not return to baseline at the hip in the FDA's follow-up data.
- The FDA label advises against Depo-Provera as a long-term (over 2 years) method unless other options are judged inadequate. Talk to your prescriber before changing anything.
- A DEXA scan measures your actual bone density, and you can book one without a referral.
Table of Contents
- Why Depo-Provera affects bone
- How much bone density loss have studies measured?
- Does bone density come back after you stop?
- Who should think harder about bone health on Depo-Provera?
- What to ask your clinician
- What a DEXA scan tells you
- Perspective
- Find a bone density scan near you
- FAQ
- Sources
Why Depo-Provera affects bone
Depo-Provera is an injection given about every three months. It suppresses ovulation, which lowers circulating estrogen. Estrogen helps keep bone remodeling in balance, so lower levels shift the balance toward bone loss. The 2024 FDA label ties the BMD decrease to this reduced serum estrogen. It is the same basic mechanism that drives bone loss after menopause.
That comparison can sound alarming, so context matters. A 2010 review by Renner and colleagues notes that BMD predicts fracture risk in postmenopausal women, but that link has not been found in premenopausal women. The same review states that no randomized controlled trial has examined fracture risk tied to DMPA. So the bone density change is well documented, while its long-term effect on fractures is less settled.
How much bone density loss have studies measured?
Numbers vary by study, age and site, but they follow a consistent pattern.
| Source | Finding |
|---|---|
| FDA label, revised July 2024 | Mean BMD decreases of 5–6% at hip and spine after up to 5 years in adults |
| ACOG Committee Opinion, June 2014 | 0.5–3.5% loss at hip and spine after 1 year; 5.7–7.5% after 2 years |
| Fertility and Sterility, 2006 | About 75% of hip loss and 90% of spine loss happened in the first 24 months |
Two things stand out. First, the curve is front-loaded: the steepest decline is in the first one to two years, with smaller declines afterward. Second, the hip and spine are the sites researchers track, because they are where osteoporotic fractures matter most.
These are group averages. Your own change could be smaller or larger, and only a measurement can tell you where you stand.
Does bone density come back after you stop?
For most adults, largely yes. The FDA label describes partial BMD recovery toward baseline during the two years after stopping. A 2006 study of women aged 25–35 found significant BMD increases through 96 weeks after discontinuation. The ACOG opinion adds that cross-sectional studies show former adult users have BMD similar to women who never used DMPA, which suggests the loss is likely transient.
Recovery is not instant or uniform, though:
- Site matters. ACOG's Committee Opinion No. 602 notes that recovery generally takes longer at the hip and femoral neck than at the spine.
- Duration matters. In the 2006 Fertility and Sterility study, 18 months after stopping, the longest users were still 4.7% below baseline at the hip and 2.9% at the spine.
- Age matters. Per the FDA label, adolescents treated for more than two years did not recover to baseline at the femoral neck and total hip, even 60 months after treatment ended.
If you stopped the shot a year ago and wonder where your bones are now, that is a measurable question.
Who should think harder about bone health on Depo-Provera?
Teens and young adults
The FDA label says loss is of particular concern in adolescence and early adulthood, when bone mass is accumulating toward its peak. It also states it is unknown whether use during these years lowers peak bone mass and raises fracture risk later in life. ACOG cautions that reassuring adult data may not fully apply to adolescents who are still developing bone rapidly.
People with other risk factors
According to the FDA label, Depo-Provera poses an additional risk for people who already have osteoporosis risk factors. It lists:
- Metabolic bone disease
- Chronic alcohol or tobacco use
- Anorexia nervosa
- Long-term use of corticosteroids or anticonvulsants
If any of these apply to you, ask your prescriber whether Depo-Provera is the right fit and whether baseline bone testing makes sense. Vitamin D status also plays into bone health, which we cover in measuring before you dose.
People nearing menopause
If you are in your late 40s, bone loss from the shot can overlap with the natural decline of perimenopause. Our guide to bone density in menopause explains how that loss peaks and when to check your risk.
What to ask your clinician
The FDA label says Depo-Provera is not recommended as a long-term method (longer than 2 years) unless other birth control options are considered inadequate. That is a prompt for a conversation, not an automatic reason to stop. Renner and colleagues report that ACOG and the WHO both conclude the contraceptive advantages of DMPA generally outweigh the theoretical skeletal concerns. They also point out that limiting duration purely over bone worries could raise the risk of unintended pregnancy and induced abortion, which carries its own health consequences.
Useful questions for your prescriber:
- How long have I been on the shot, and does my history put me near the two-year mark?
- Do I have any of the risk factors the FDA label lists?
- Would a baseline or follow-up bone density scan change what we decide?
- If I switch methods, when should I recheck my bones?
- What calcium, vitamin D and weight-bearing exercise habits fit my situation?
Do not stop your injections on your own because of this article. Gaps in contraception carry real risks, and the right call depends on your age, history and goals.
What a DEXA scan tells you
A DEXA scan uses very low-dose X-rays to measure bone mineral density at the hip and spine, the same sites studied in the Depo-Provera research. Results come as a T-score or, for younger people, a Z-score compared with people of your age. Our guide to reading your DEXA results in four steps walks through what the numbers mean and what to do next.
Timing matters. Because the steepest loss happens in the first two years, a scan at a meaningful interval (for example around or after two years of use, or after you stop) is more informative than one taken a few weeks in. We break down this logic in DEXA scan timing, and general intervals by risk level are in our DEXA scan frequency guide.
Two practical notes:
- Insurance guidelines for routine screening often focus on women 65 and older (see our screening guidelines), so younger Depo-Provera users may not qualify for coverage. Cash pricing is a common route.
- If you could be pregnant, tell the clinic first. Radiation from DEXA is very low, and our piece on DEXA safety during pregnancy explains the details.
Perspective
We built Dexascans around a simple observation: people often hear that a medication may affect their bones, then are told nothing about how to find out what is actually happening in their own skeleton. Averages from studies are useful, but they are not you.
Our view is that a measured number beats a worry. A DEXA scan is the standard tool for bone density, and it does not need to involve a referral, a hospital bill or a long wait. We list verified clinics, show cash prices up front and let you book directly, so a conversation with your prescriber can start from data.
If you have used Depo-Provera for a couple of years, stopped recently, or carry other risk factors, a baseline scan gives you something to compare against later. That is the practical value: not alarm, but a reference point.
Erik
Find a bone density scan near you
Dexascans lists verified DEXA clinics across the U.S. You can search by city or ZIP, compare cash prices and book directly with the clinic, without a physician referral. Start with our bone density test page for costs, T-scores and where to get one.
If you are in Denver, you can also compare local options on the Denver DEXA scan page.
FAQ
Does Depo-Provera permanently damage bones?
In adults, evidence suggests the loss is likely transient, since former adult users show BMD similar to never-users in cross-sectional studies, per ACOG. Recovery can take longer at the hip than the spine. For adolescents treated more than two years, the FDA label reports incomplete recovery at the hip even 60 months later.
How long can you stay on Depo-Provera?
The FDA label does not recommend it as a long-term method beyond 2 years unless other options are considered inadequate. Some clinicians continue it longer after weighing benefits and risks with the patient. Your prescriber can help you decide based on your history.
Should I get a DEXA scan if I use Depo-Provera?
No source we reviewed requires one for every user. A scan can make sense if you have used it for around two years or more, have other bone risk factors, or want a baseline. Ask your prescriber, and see our DEXA frequency guide for timing.
Does Depo-Provera raise fracture risk?
BMD drops with use, but the 2010 Renner review notes no randomized trial has examined fracture risk tied to DMPA. BMD predicts fractures after menopause, but that link has not been shown in premenopausal women. Whether early use lowers peak bone mass and later fracture risk is unknown per the FDA label.
Sources
- Depo-Provera CI prescribing information (FDA label, revised July 2024)
- Depot Medroxyprogesterone Acetate and Bone Effects (ACOG, 2014)
- Committee Opinion No. 602 (Obstetrics & Gynecology, 2014)
- Bone mineral density loss and recovery during 48 months (Fertility and Sterility, 2006)
- Bone mineral density in women aged 25-35 years receiving DMPA (PubMed, 2006)
- Depot Medroxyprogesterone Acetate Contraceptive Injections (Renner et al., 2010)